{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:04:15Z","timestamp":1761750255754,"version":"build-2065373602"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>This bibliometric analysis aims to explore global trends, research hotspots, and future directions in multidrug resistance of multiple myeloma (MM), providing insights for overcoming resistance mechanisms and optimizing therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We analyzed 3300 publications indexed in the Web of Science Core Collection (2015\u20132024) using CiteSpace and VOSviewer. Multidimensional evaluations of countries\/regions, institutions, authors, journals, and keywords were conducted, supplemented by visual network mapping to elucidate research dynamics and collaborative patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Annual MM drug resistance publications exhibited sustained growth, with a notable surge during 2022 to 2024. The United States (36.4%) and China (28.6%) dominated research output, while Harvard Medical School emerged as the most influential institution. Keyword clustering identified 5 core research domains: pharmacological interventions and therapies, resistance mechanisms and molecular pathways, cellular drug resistance mechanisms, tumor microenvironment and immunoregulation, and fundamental biology and diagnostics. Current research focuses on microenvironment-mediated resistance mechanisms and novel immunotherapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study delineates the intellectual landscape of MM drug resistance research, emphasizing key contributors, evolving priorities, and emerging frontiers. The findings offer actionable intelligence for guiding future investigations and evidence-based policymaking, potentially accelerating the development of optimized therapeutic approaches for chemoresistant MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044279","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:05:40Z","timestamp":1757354740000},"page":"e44279","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Exploring research advances and future trends in drug resistance in multiple myeloma: A comprehensive bibliometric analysis"],"prefix":"10.1097","volume":"104","author":[{"given":"Xuanyu","family":"Yang","sequence":"first","affiliation":[{"name":"School of Ophthalmology and Optometry, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangzhen","family":"Lin","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siteng","family":"Zheng","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Gao","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyang","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Mei","sequence":"additional","affiliation":[{"name":"School of Ophthalmology and Optometry, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Xie","sequence":"additional","affiliation":[{"name":"School of Ophthalmology and Optometry, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayu","family":"Ke","sequence":"additional","affiliation":[{"name":"School of Food Science and Technology, Nanchang University, Nanchang, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2522-6631","authenticated-orcid":false,"given":"Ling","family":"Ling","sequence":"additional","affiliation":[{"name":"Nanchang Bright Eye Hospital, Nanchang, Jiangxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251029","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/480S33a","article-title":"Multiple myeloma.","volume":"480","author":"Brody","year":"2011","journal-title":"Nature"},{"key":"R2-20251029","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma.","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"R3-20251029","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma.","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-20251029","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2020).","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"R5-20251029","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma.","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"R6-20251029","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00277-024-05730-y","article-title":"Therapeutic progress in relapsed\/refractory multiple myeloma.","volume":"103","author":"Chen","year":"2024","journal-title":"Ann Hematol"},{"issue":"Suppl 7","key":"R7-20251029","doi-asserted-by":"crossref","first-page":"vii143","DOI":"10.1093\/annonc\/mdq370","article-title":"Multiple myeloma.","volume":"21","author":"Dimopoulos","year":"2010","journal-title":"Ann Oncol"},{"key":"R8-20251029","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood.V79.1.213.213","article-title":"A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA.","volume":"79","author":"Moalli","year":"1992","journal-title":"Blood"},{"key":"R9-20251029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/mol.114.092114","article-title":"Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).","volume":"86","author":"Niewerth","year":"2014","journal-title":"Mol Pharmacol"},{"key":"R10-20251029","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.2008.07454.x","article-title":"The prognostic significance of 8p21 deletion in multiple myeloma.","volume":"144","author":"Sutlu","year":"2009","journal-title":"Br J Haematol"},{"key":"R11-20251029","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2013.148","article-title":"Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.","volume":"27","author":"Stessman","year":"2013","journal-title":"Leukemia"},{"key":"R12-20251029","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"R13-20251029","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/1097-0142(19950201)75:3<815::AID-CNCR2820750311>3.0.CO;2-R","article-title":"A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.","volume":"75","author":"Dalton","year":"1995","journal-title":"Cancer"},{"key":"R14-20251029","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/0959-8049(96)00111-6","article-title":"Pharmacological considerations in the modulation of multidrug resistance.","volume":"32A","author":"Fisher","year":"1996","journal-title":"Eur J Cancer"},{"key":"R15-20251029","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00001813-199212000-00013","article-title":"SDZ PSC-833 \u2013 a novel potent in vitro chemosensitizer in multiple myeloma.","volume":"3","author":"Jonsson","year":"1992","journal-title":"Anticancer Drugs"},{"key":"R16-20251029","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1054\/drup.1999.0094","article-title":"NF-kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappa B.","volume":"2","author":"Cusack","year":"1999","journal-title":"Drug Resist Updat"},{"key":"R17-20251029","doi-asserted-by":"crossref","first-page":"e0223994","DOI":"10.1371\/journal.pone.0223994","article-title":"Visualizing a field of research: a methodology of systematic scientometric reviews.","volume":"14","author":"Chen","year":"2019","journal-title":"PLoS One"},{"key":"R18-20251029","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping.","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"issue":"Suppl 1","key":"R19-20251029","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1073\/pnas.0307513100","article-title":"Searching for intellectual turning points: progressive knowledge domain visualization.","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R20-20251029","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.07-9492LSF","article-title":"Comparison of pubmed, scopus, web of science, and google scholar: strengths and weaknesses.","volume":"22","author":"Falagas","year":"2008","journal-title":"FASEB J"},{"key":"R21-20251029","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s11192-020-03690-4","article-title":"Google scholar, microsoft academic, scopus, dimensions, web of science, and opencitations\u2019 COCI: a multidisciplinary comparison of coverage via citations.","volume":"126","author":"Mart\u00edn-Mart\u00edn","year":"2021","journal-title":"Scientometrics"},{"key":"R22-20251029","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma.","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"R23-20251029","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma.","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R24-20251029","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma.","volume":"384","author":"Nikhil","year":"2021","journal-title":"N Engl J Med"},{"key":"R25-20251029","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study.","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet (London, England)"},{"key":"R26-20251029","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma.","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"R27-20251029","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"R28-20251029","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review.","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"R29-20251029","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-024-01030-w","article-title":"Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.","volume":"14","author":"Callander","year":"2024","journal-title":"Blood Cancer J"},{"key":"R30-20251029","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III Trial.","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"R31-20251029","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"R32-20251029","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma.","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"key":"R33-20251029","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial.","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"key":"R34-20251029","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","article-title":"Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.","volume":"13","author":"Ng","year":"2022","journal-title":"Nat Commun"},{"key":"R35-20251029","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.","volume":"13","author":"Vo","year":"2022","journal-title":"Nat Commun"},{"key":"R36-20251029","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","article-title":"Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma.","volume":"115","author":"Demchenko","year":"2010","journal-title":"Blood"},{"key":"R37-20251029","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma.","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"R38-20251029","first-page":"2599","article-title":"Ubiquitin receptor PSMD4\/Rpn10 is a novel therapeutic target in multiple myeloma.","volume":"141","author":"Du","year":"2023","journal-title":"Blood"},{"key":"R39-20251029","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"key":"R40-20251029","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","article-title":"Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages.","volume":"14","author":"Cheng","year":"2024","journal-title":"Blood Cancer J"},{"key":"R41-20251029","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.1993.11.9.1629","article-title":"Modulation of multidrug resistance: at the threshold.","volume":"11","author":"Sikic","year":"1993","journal-title":"J Clin Oncol"},{"key":"R42-20251029","doi-asserted-by":"crossref","first-page":"36062","DOI":"10.1074\/jbc.M007204200","article-title":"Inhibition of NF-\u03baB activation by arsenite through reaction with a critical cysteine in the activation loop of I\u03baB Kinase*.","volume":"275","author":"Kapahi","year":"2000","journal-title":"J Biol Chem"},{"key":"R43-20251029","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2003.06.001","article-title":"Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"key":"R44-20251029","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/sj.leu.2401605","article-title":"Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.","volume":"13","author":"Wuchter","year":"1999","journal-title":"Leukemia"},{"key":"R45-20251029","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma.","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"R46-20251029","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM.","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"R47-20251029","doi-asserted-by":"crossref","first-page":"13162","DOI":"10.1073\/pnas.1608067113","article-title":"Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.","volume":"113","author":"Hideshima","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"R48-20251029","doi-asserted-by":"crossref","first-page":"8567","DOI":"10.1073\/pnas.0503221102","article-title":"Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.","volume":"102","author":"Hideshima","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R49-20251029","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1111\/j.1742-4658.2009.07041.x","article-title":"Sustained activation of ERK1\/2 by NGF induces microRNA-221 and 222 in PC12 cells.","volume":"276","author":"Terasawa","year":"2009","journal-title":"FEBS J"},{"key":"R50-20251029","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/0008-5472.CAN-15-0457","article-title":"Targeting the miR-221-222\/PUMA\/BAK\/BAX pathway abrogates dexamethasone resistance in multiple myeloma.","volume":"75","author":"Zhao","year":"2015","journal-title":"Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:00:24Z","timestamp":1761750024000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":50,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044279","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"2025-05-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}